The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Federico Innocenti
Employment - Abbvie
Honoraria - Tempus
Consulting or Advisory Role - Emerald Lake Safety; Symberix
Patents, Royalties, Other Intellectual Property - United States Patent, serial number: 09/835,082; United States Patent, serial number: 16/932,002; United States Patent, serial number: 60/446,942; United States Patent, serial number: 63/169,301
 
Ryan Sun
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)